• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Proceedings of the second annual dengue endgame summit: A call to action.第二届登革热终结峰会会议记录:行动呼吁
PLoS Negl Trop Dis. 2025 Apr 28;19(4):e0013028. doi: 10.1371/journal.pntd.0013028. eCollection 2025 Apr.
2
Proceedings of the dengue endgame summit: Imagining a world with dengue control.登革热终结峰会会议记录:设想一个具有登革热控制能力的世界。
Vaccine. 2024 Oct 3;42(23):126071. doi: 10.1016/j.vaccine.2024.06.038. Epub 2024 Jun 17.
3
Dengue: knowledge gaps, unmet needs, and research priorities.登革热:知识空白、未满足的需求及研究重点
Lancet Infect Dis. 2017 Mar;17(3):e88-e100. doi: 10.1016/S1473-3099(16)30473-X. Epub 2017 Feb 7.
4
Call to action for dengue vaccine failure.应对登革热疫苗失败的行动呼吁。
Emerg Infect Dis. 2013 Aug;19(8):1335-7. doi: 10.3201/eid1908.121864.
5
Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.登革病毒2型DNA疫苗的病毒样颗粒分泌及基因型依赖性免疫原性
J Virol. 2014 Sep;88(18):10813-30. doi: 10.1128/JVI.00810-14. Epub 2014 Jul 9.
6
Dengue mouse models for evaluating pathogenesis and countermeasures.登革热小鼠模型用于评估发病机制和对策。
Curr Opin Virol. 2020 Aug;43:50-58. doi: 10.1016/j.coviro.2020.09.001. Epub 2020 Sep 17.
7
Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control.登革病毒发病机制的分子洞察及其对疾病控制的意义
Cell. 2015 Jul 30;162(3):488-92. doi: 10.1016/j.cell.2015.07.005.
8
Anti-dengue Vaccines: From Development to Clinical Trials.抗登革热疫苗:从研发到临床试验。
Front Immunol. 2020 Jun 18;11:1252. doi: 10.3389/fimmu.2020.01252. eCollection 2020.
9
Prospects for a dengue virus vaccine.登革热病毒疫苗的前景。
Nat Rev Microbiol. 2007 Jul;5(7):518-28. doi: 10.1038/nrmicro1690.
10
Dengue research opportunities in the Americas.美洲的登革热研究机会。
J Infect Dis. 2012 Oct 1;206(7):1121-7. doi: 10.1093/infdis/jis351. Epub 2012 Jul 9.

本文引用的文献

1
B cell receptor dependent enhancement of dengue virus infection.B 细胞受体依赖性增强登革病毒感染。
PLoS Pathog. 2024 Oct 31;20(10):e1012683. doi: 10.1371/journal.ppat.1012683. eCollection 2024 Oct.
2
Obesity Is Associated With Increased Pediatric Dengue Virus Infection and Disease: A 9-Year Cohort Study in Managua, Nicaragua.肥胖与儿童登革热病毒感染和疾病的增加有关:尼加拉瓜马那瓜的一项 9 年队列研究。
Clin Infect Dis. 2024 Oct 15;79(4):1102-1108. doi: 10.1093/cid/ciae360.
3
Proceedings of the dengue endgame summit: Imagining a world with dengue control.登革热终结峰会会议记录:设想一个具有登革热控制能力的世界。
Vaccine. 2024 Oct 3;42(23):126071. doi: 10.1016/j.vaccine.2024.06.038. Epub 2024 Jun 17.
4
mRNA-encoded Cas13 can be used to treat dengue infections in mice.信使核糖核酸编码的Cas13可用于治疗小鼠的登革热感染。
Nat Microbiol. 2024 Aug;9(8):2160-2172. doi: 10.1038/s41564-024-01726-6. Epub 2024 Jun 5.
5
Primary exposure to Zika virus is linked with increased risk of symptomatic dengue virus infection with serotypes 2, 3, and 4, but not 1.初次感染 Zika 病毒会增加感染血清型 2、3 和 4 登革热病毒的风险,但不会增加感染血清型 1 的风险。
Sci Transl Med. 2024 May 29;16(749):eadn2199. doi: 10.1126/scitranslmed.adn2199.
6
Antibodies to D7L salivary proteins as a new serological tool to estimate human exposure to mosquitoes.抗 D7L 唾液蛋白抗体作为一种新的血清学工具来估计人类接触蚊子的情况。
Front Immunol. 2024 May 1;15:1368066. doi: 10.3389/fimmu.2024.1368066. eCollection 2024.
7
Identification and characterization of a nonbiological small-molecular mimic of a Zika virus conformational neutralizing epitope.鉴定和表征寨卡病毒构象中和表位的非生物学小分子模拟物。
Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2312755121. doi: 10.1073/pnas.2312755121. Epub 2024 May 14.
8
A scoping literature review of global dengue age-stratified seroprevalence data: estimating dengue force of infection in endemic countries.全球登革热分年龄血清流行率数据的范围界定文献综述:估计流行国家登革热感染率。
EBioMedicine. 2024 Jun;104:105134. doi: 10.1016/j.ebiom.2024.105134. Epub 2024 May 7.
9
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.四价登革热疫苗初免-加强方案免疫后登革病毒 1 型人体挑战的疗效和免疫原性:一项开放标签、1 期临床试验。
Lancet Infect Dis. 2024 Aug;24(8):896-908. doi: 10.1016/S1473-3099(24)00100-2. Epub 2024 Apr 25.
10
Low-dose dengue virus 3 human challenge model: a phase 1 open-label study.低剂量登革病毒 3 型人体挑战模型:一项 1 期开放性标签研究。
Nat Microbiol. 2024 May;9(5):1356-1367. doi: 10.1038/s41564-024-01668-z. Epub 2024 Apr 1.

第二届登革热终结峰会会议记录:行动呼吁

Proceedings of the second annual dengue endgame summit: A call to action.

作者信息

Hardy Céline S C, Bahr Lauren E, Rothman Alan L, Anderson Kathryn B, Barba-Spaeth Giovanna, Weiskopf Daniela, Ooi Eng Eong, Marques Ernesto T A, Bonsignori Mattia, Barrett Alan D T, Kirkpatrick Beth D, Castanha Priscila M S, Hamins-Puertolas Marco, Christofferson Rebecca C, Dimopoulos George, Oliveira Fabiano, Chiang Lillian W, Ko Albert I, Gunale Bhagwat, Kulkarni Prasad, Perkins T Alex, Dorigatti Ilaria, Stewart Telisa, Shaw Jana, Johansson Michael A, Thomas Stephen J, Waickman Adam T

机构信息

Department of Microbiology and Immunology, Upstate Medical University, Syracuse, New York, United States of America.

Department of Cell and Molecular Biology, Institute for Immunology and Informatics, University of Rhode Island, Kingston, Rhode Island, United States of America.

出版信息

PLoS Negl Trop Dis. 2025 Apr 28;19(4):e0013028. doi: 10.1371/journal.pntd.0013028. eCollection 2025 Apr.

DOI:10.1371/journal.pntd.0013028
PMID:40294026
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12036847/
Abstract

On August 7-9, 2024, the second annual dengue "endgame" summit was held in Syracuse, NY, hosted by the Global Health Institute at SUNY Upstate Medical University. The meeting brought together attendees from around the world, with talks spanning healthcare, government control programs, basic research, and medical countermeasure development efforts. The summit goal was to work toward a better understanding of what dengue control could look like and the steps required to reach such a goal. The objectives of the meeting were to discuss the current global state of dengue, what dengue "control" might look like, and to discuss actionable pathways for achieving dengue control. Topics covered throughout the meeting included DENV immunity and pathogenesis, challenges in countermeasure development, innovative vector control strategies, dengue diagnostics, addressing challenges in science communication, and vaccine hesitancy. Several fundamental knowledge gaps were repeatedly highlighted by the summit attendees and were cited as critical barriers to the development, deployment, and evaluation of effective dengue countermeasures. These gaps include (1) the lack of a broadly applicable immunologic biomarker/correlate of DENV immunity and (2) the lack of universally accepted/applicable metrics for quantifying dengue severity in the setting of countermeasure evaluations. In addition, the lack of clear and consistent international leadership in the global dengue control effort was cited as a barrier to widespread and synergistic research and countermeasure development/deployment activities. Despite these persistent roadblocks, summit attendees expressed optimism that holistic and multi-tiered approaches-incorporating optimal use of existing and nascent countermeasure technologies deployed in collaboration with local communities-could be effective in progressing toward dengue control.

摘要

2024年8月7日至9日,第二届年度登革热“终结”峰会在纽约州锡拉丘兹举行,由纽约州立大学上州医科大学全球健康研究所主办。会议汇聚了来自世界各地的与会者,讨论内容涵盖医疗保健、政府防控项目、基础研究以及医学对策开发工作。峰会的目标是努力更好地理解登革热防控可能的样子以及实现这一目标所需的步骤。会议的目的是讨论登革热的当前全球状况、登革热“防控”可能是什么样,并讨论实现登革热防控的可行途径。会议涵盖的主题包括登革病毒免疫和发病机制、对策开发中的挑战、创新的病媒控制策略、登革热诊断、应对科学传播中的挑战以及疫苗犹豫问题。峰会与会者多次强调了几个基本的知识空白,并将其视为有效登革热对策开发、部署和评估的关键障碍。这些空白包括:(1)缺乏广泛适用的免疫生物标志物/登革病毒免疫相关指标;(2)在对策评估中缺乏普遍接受/适用的量化登革热严重程度的指标。此外,全球登革热防控努力缺乏明确和一致的国际领导被认为是广泛和协同的研究以及对策开发/部署活动的障碍。尽管存在这些持续的障碍,峰会与会者表示乐观地认为,结合与当地社区合作最佳利用现有和新兴对策技术的整体和多层次方法,可能有效地推动登革热防控工作取得进展。